History of clinically significant or uncontrolled cardiac disease, including congestive heart failure (New York Heart Association functional classification >= ), angina, myocardial infarction or ventricular arrhythmia.
Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class  or  congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within  months prior to randomization
Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or Class  or  congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within  months prior to randomization
Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class  or  congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within  months prior to enrollment
Has a clinically significant cardiovascular disease such as unstable angina, myocardial infarction, or acute coronary syndrome within ? days prior to start of study treatment, symptomatic or uncontrolled arrhythmia, congestive heart failure, or any Class  or  cardiac disease as defined by the New York Heart Association Functional Classification
Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class  or  congestive heart failure as defined by the New York Heart Association Functional classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within  months prior to randomization.
Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class  or  congestive heart failure as defined by the New York Heart Association functional classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within  months prior to enrollment on the study
Active uncontrolled cardiac disease, including cardiomyopathy, congestive heart failure (New York Heart Association functional classification of >= ; including individuals who currently use digitalis, beta-blockers, or calcium channel blockers specifically for congestive heart failure), unstable angina, myocardial infarction within  months of enrollment, or ventricular arrhythmia
Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class  or  congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within  months prior to randomization
Clinically significant cardiovascular disease such as unstable angina, myocardial infarction, or acute coronary syndrome within =< days prior to registration, symptomatic or uncontrolled arrhythmia, congestive heart failure, or any class  or  cardiac disease as defined by the New York Heart Association Functional Classification
Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class  or  congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome =<  months prior to pre-randomization
Any life-threatening illness, medical condition, or organ system dysfunction, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, active autoimmune disorder, or psychiatric illness/social situations that, in the investigators opinion, could compromise the subjects safety or put the study outcomes at undue risk; currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class  or  congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within  months prior to enrollment
Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class  or  congestive heart failure as defined by the New York Heart Association functional classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within  months prior to start of first study treatment
Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class  or  congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within  months prior to enrollment
Current uncontrolled cardiac disease such as angina or myocardial infarction, congestive heart failure including New York Heart Association functional classification of , or arrhythmia requiring treatment
Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class  or  congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within  months prior to randomization
History of clinically significant or uncontrolled cardiac disease, including congestive heart failure, angina, myocardial infarction, arrhythmia, including New York Heart Association functional classification of three
Currently active clinically significant cardiovascular disease, such as uncontrolled arrhythmia, congestive heart failure, any class  or  cardiac disease, as defined by the New York Heart Association Functional Classification, or history of myocardial infarction within  months prior to first dose with study drug
Currently active clinically significant cardiovascular disease such as uncontrolled arrhythmia, congestive heart failure, or class  or  congestive heart failure as defined by the New York Heart Association Functional Classification, or history of myocardial infarction unstable angina, or acute coronary syndrome within  months prior to enrollment in the study
Active uncontrolled cardiac disease, including cardiomyopathy, congestive heart failure (New York Heart Association functional classification of ?; including individuals who currently use digitalis, beta -blockers, or calcium channel blockers specifically for congestive heart failure), unstable angina, myocardial infarction within  months of enrollment, or ventricular arrhythmia
Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class  or  congestive heart failure as defined by the New York Heart Association Function Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within  months prior to screening
No history of a congestive heart failure, myocardial infarction, unstable angina, uncontrolled arrhythmia, or any class  or  cardiac disease as defined by the New York Heart Association Functional Classification in the last  months
Currently active clinically significant cardiovascular disease such as uncontrolled arrhythmia, congestive heart failure, or class  or  congestive heart failure as defined by the New York Heart Association Functional Classification, or history of myocardial infarction, unstable angina, or acute coronary syndrome within  months prior to randomization
Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class  or  congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within  months prior to randomization
Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class  or  congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within  months prior to randomization
Active uncontrolled cardiac disease, including cardiomyopathy, congestive heart failure (New York Heart Association functional classification of >= , including individuals who currently use digitalis specifically for congestive heart failure), unstable angina, myocardial infarction within  month of enrollment or ventricular arrhythmia
Currently active, clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, class  or  congestive heart failure as defined by the New York Heart Association Functional Classification, or history of myocardial infarction, unstable angina or acute coronary syndrome within  months of screening
Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class  or  congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within  months prior to randomization
Active uncontrolled cardiac disease, including cardiomyopathy, congestive heart failure (New York Heart Association functional classification of >= ), unstable angina, myocardial infarction within  months of enrollment, or ventricular arrhythmia
Participant has active, uncontrolled cardiac disease, including cardiomyopathy, congestive heart failure (New York Heart Association functional classification of >= ), unstable angina, myocardial infarction within  months of enrollment, or ventricular arrhythmia
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements; currently active clinically significant cardiovascular disease such as uncontrolled arrhythmia, congestive heart failure or class  or  congestive heart failure as defined by the New York Heart Association Functional Classification, or history of myocardial infarction, unstable angina or acute coronary syndrome within  months prior to randomization
Currently active clinically significant cardiovascular disease such as uncontrolled arrhythmia, congestive heart failure, or any class  or  congestive heart failure as defined by the New York Heart Association Functional Classification, or history of myocardial infarction, unstable angina or acute coronary syndrome within  months prior to on-study registration
Has a clinically significant cardiovascular disease such as unstable angina, myocardial infarction, or acute coronary syndrome within ? days prior to start of study treatment, symptomatic or uncontrolled arrhythmia, congestive heart failure, or any Class  or  cardiac disease as defined by the New York Heart Association Functional Classification
Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or Class  or  congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within  months prior to randomization.
Patients with a cardiac ejection fraction (as measured by either multi gated acquisition scan [MUGA] or echocardiogram) < % are excluded; currently active clinically significant cardiovascular disease such as uncontrolled arrhythmia, congestive heart failure, any class  or  cardiac disease as defined by the New York Heart Association Functional Classification, or history of myocardial infarction within  months prior to first dose with study drug
Current uncontrolled cardiac disease such as angina or myocardial infarction, congestive heart failure including New York Heart Association functional classification of , or arrhythmia requiring treatment.
Significant or uncontrolled intercurrent condition including, but not limited to:\r\n* Infection other than HIV, hepatitis B, or hepatitis C that is symptomatic or requires systemic treatment\r\n* Opportunistic infection within  days prior to enrollment\r\n* Currently active clinically significant cardiovascular disease such as uncontrolled arrhythmia, congestive heart failure, any class  or  cardiac disease as defined by the New York Heart Association Functional Classification, or history of myocardial infection within  months prior to enrollment\r\n* History of stroke or intracranial hemorrhage within  months prior to enrollment\r\n* History of class B or class C cirrhosis, per the modified Child-Pugh classification\r\n* Psychiatric illness that would limit compliance
Currently active clinically significant cardiovascular disease such as uncontrolled arrhythmia, congestive heart failure, or class  or  congestive heart failure as defined by the New York Heart Association Functional Classification, or history of myocardial infarction, unstable angina, or acute coronary syndrome within  months prior to first dose with study drug
Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class  or  congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within  months prior to enrollment
Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class  or  congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within  months prior to randomization
EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class  or  congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within  months prior to randomization
Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class  or higher congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within  months prior to randomization
